TNFRSF10D: A Promising Target for Cancer and Other Diseases (G8793)

Target Name: TNFRSF10D

NCBI ID: G8793

TNFRSF10D

TNFRSF10D: A Promising Target for Cancer and Other Diseases

The TNFRSF10D protein, also known as TRIM-20, is a protein that is expressed in various tissues throughout the body, including the brain, spleen, heart, and lungs. It is a key regulator of the tumor necrosis factor-alpha (TNF-伪) signaling pathway, which is involved in a wide range of physiological processes in the body, including immune response, inflammation, and cell death.

One of the unique features of TNFRSF10D is its ability to interact with the proteinTrail, which is a death domain protein that is also known as TNF-伪-responsive intracellular signaling protein (RIP). Trail has been shown to play a role in a variety of cellular processes, including cell death, cell signaling, and inflammation.

The interaction between TNFRSF10D and Trail is critical for the regulation of cellular processes that are important for both normal development and cancer progression. Specifically, the combination of TNFRSF10D and Trail has been shown to promote the death domain protein's ability to induce cell death, which may be a potential drug target for cancer therapy.

One of the key benefits of targeting Trail is its potential to inhibit the activity of various cellular signaling pathways that are involved in cancer growth and progression. For example, the TNF-伪 signaling pathway has been shown to be involved in the regulation of cancer cell survival, and inhibiting its activity may be a potential way to treat cancer.

Targeting Trail has also been shown to be effective in treating a variety of diseases, including neurodegenerative disorders, autoimmune diseases, and cancer. For example, the combination of Trail and TNFRSF10D has been shown to be effective in treating neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, by inhibiting the activity of the TNF-伪 signaling pathway.

In addition to its potential therapeutic applications, the TNFRSF10D protein is also a potential biomarker for a variety of diseases. The ability of TNFRSF10D to interact with Trail has been shown to be associated with the development and progression of a wide range of diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

Overall, the TNFRSF10D protein is a promising target for cancer and other diseases, due to its ability to interact with the Trail death domain protein. Further research is needed to fully understand the role of this protein in cellular processes and its potential as a drug or biomarker.

Protein Name: TNF Receptor Superfamily Member 10d

Functions: Receptor for the cytotoxic ligand TRAIL (PubMed:9430226). Contains a truncated death domain and hence is not capable of inducing apoptosis but protects against TRAIL-mediated apoptosis (PubMed:9537512). Reports are contradictory with regards to its ability to induce the NF-kappa-B pathway. According to PubMed:9382840, it cannot but according to PubMed:9430226, it can induce the NF-kappa-B pathway (PubMed:9382840, PubMed:9430226)

The "TNFRSF10D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TNFRSF10D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets